

Akzo Nobel divests PVC additives business

Arnhem, the Netherlands, March 15, 2007 — Akzo Nobel has divested its Akcros Chemicals PVC additives business to UK-based private investment firm GIL Investments. Financial details were not disclosed.

Under the terms of the deal, the company's sites in Eccles, UK, and New Brunswick in the United States—along with all of the approximately 160 employees at these locations—will be transferred to the new owner.

An agreement has also been reached whereby Akzo Nobel will continue to operate two smaller, related production operations in Greiz, Germany, and Itupeva in Brazil. Employees at these two locations—who will provide toll production services to the new owner—will therefore remain with Akzo Nobel.

“Transferring the bulk of the PVC additives activities to a new owner is the best way forward for the business, which will continue to operate under its current name,” explained Leif Darnier, member of Akzo Nobel's Board of Management responsible for Chemicals. “This transaction means that we have just one more divestment to finalize before completing the strategic realignment of our Chemicals portfolio.”

Regulatory approvals will be sought as and where appropriate.

Akcros Chemicals is one of the world leaders in the field of additives for the processing and manufacturing of PVC products. The business' range of additives includes stabilizers, biocides and bonding agents.

Headquartered in the Midlands, GIL Investments has an established track record of acquiring and developing businesses and adding value over the long term.

- - -

Note to editors

Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,880 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the first quarter will be published on April 24, 2007.

Internet: www.akzonobel.com

Not for publication – for more information

Akzo Nobel nv
Corporate Media Relations, tel. +31 26 366 43 43
Contact: Heleen van de Lustgraaf

Akzo Nobel nv
Velperweg 76
P.O. Box 9300
6800 SB Arnhem
The Netherlands
Tel +31 26 366 43 43
Fax +31 26 366 49 40

Safe Harbor Statement*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.